Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7511)
All Articles published online
|
Publishing Process of This Article
|
Nov 6, 2015 (publication date) through Nov 21, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ohkoshi S, Hirono H, Yamagiwa S. Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther 2015; 6(4): 114-119 [PMID: 26558145 DOI: 10.4292/wjgpt.v6.i4.114] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v6/i4/114.htm |
| Number | Citing Articles |
| 1 |
Federico Sáez-Royuela, Ester Badia. Hepatitis C: Is Regression of Advanced Fibrosis Possible After Treatment?. European Medical Journal 2016; : 126 doi: 10.33590/emj/10310547
|
| 2 |
Sean M. McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 2016; 9(2): 287 doi: 10.1586/17512433.2016.1129272
|
| 3 |
Qianqian Zhang, Yang Wang, Naicui Zhai, Hongxiao Song, Haijun Li, Yang Yang, Tianyang Li, Xiaolin Guo, Baorong Chi, Junqi Niu, Ian Nicholas Crispe, Lishan Su, Zhengkun Tu. HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway. Scientific Reports 2016; 6(1) doi: 10.1038/srep36160
|
| 4 |
Valentina Zuccaro, Paola Columpsi, Alice Apollinari, Paolo Sacchi, Marco Mussa, Andrea Schimmenti, Maria Grazia Lucà, Stefano Fagiuoli, Raffaele Bruno. Emerging biological agents for hepatitis C. Expert Opinion on Emerging Drugs 2016; 21(2): 219 doi: 10.1080/14728214.2016.1184645
|
| 5 |
Amr Shaaban Hanafy, Mohamed A. Bassiony, Mohammad Abd Alkhalik Basha. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?. Hepatology International 2019; 13(2): 165 doi: 10.1007/s12072-019-09933-8
|
| 6 |
T.C. Wirth, M.P. Manns. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Annals of Oncology 2016; 27(8): 1467 doi: 10.1093/annonc/mdw219
|
| 7 |
Tangui Barré, Fabienne Marcellin, Vincent Di Beo, Jessica Delorme, Teresa Rojas Rojas, Philippe Mathurin, Camelia Protopopescu, François Bailly, Marion Coste, Nicolas Authier, Maria Patrizia Carrieri, Benjamin Rolland. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS‐FANTASIO study). Addiction 2020; 115(3): 573 doi: 10.1111/add.14820
|
| 8 |
Mohamed El Kassas, Nermeen Abdeen, Dalia Omran, Mohamed Alboraie, Mohamed Salaheldin, Mohamed Eltabbakh, Rasha Farghaly, Mohammed Emadeldeen, Shimaa Afify, Ahmad Sweedy, Ahmed Ghalwash, Amr Abbass, Sameera Ezzat, Marwa Tahoon, Helmy M. ELshazly, Hassan Hamdy, Heba Omar. Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e877 doi: 10.1097/MEG.0000000000002287
|
| 9 |
Dipesh Kumar Yadav, Rajesh Kumar Yadav, Tingbo Liang. Controversies in Liver Transplantation - Recent Challenges and Future Perspectives. 2023; doi: 10.5772/intechopen.108906
|
| 10 |
Mohamed Darwish Ahmed Abd Alla, Mostafa Kamel El Awady, Reham M. Dawood, Mostafa Abdelaziz Elhawary, Shabaan Salah Al-Azhari, Al-Shazly Gaber Mohamed Galal. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. Archives of Virology 2018; 163(10): 2765 doi: 10.1007/s00705-018-3922-7
|